BlogHotel.orgAccueil | Créer un blog | Imprimer la page Imprimer | Blog hasard Au hasard | Chercher des blogs Rechercher | Entrer dans le chat du blog Chat | | Jeux Jeux | Adminitration et édition du Blog Manager

shinenewstop Accueil | Profil | Archives | Amis
shinenewstop

Plecanatide (Trulance) for Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation9/9/2019

Constipation is the difficult or infrequent passage of stool, often accompanied by straining or a sensation of incomplete evacuation. Chronic idiopathic constipation (CIC) is a functional gastro intestinal (GI) disorder with features like those of constipation that occur for at least three months, but there is usually no evident underlying physiological abnormality.1,2 Although a number of definitions of CIC have been proposed, the Rome criteria are most often used in clinical trials and, therefore, most relevant when evaluating medications to manage this condition. The Rome criteria look at the frequency of straining, lumpy or hard stools, and sensation of incomplete evacuation, among other symptoms. The prevalence of CIC in North America is approximately 14%.3 Traditional treatment options for chronic constipation include lifestyle modifications, such as increased fluid intake and increased exercise.4 Fluid works to increase stool volume by augmenting luminal fluid, and increasing exercise improves motility by decreasing GI transit time.5 Fiber therapy is considered an effective option for the management of CIC, although the side effects can limit use. Osmotic laxatives and some stimulant laxatives have been studied and can also provide benefit.1,2.Plecanatide powder

Prior to 2017, there were only two medications approved for adults with CIC: linaclotide (Linzess, Allergan) and lubiprostone (Amitiza, Sucampo AG). Linaclotide is a guanylate cyclase-C (GC-C) agonist, and lubiprostone is a chloride-channel activator.6 Both pro-secratory agents have been shown to be effective and well tolerated for the treatment of adults with CIC. Linaclotide is also approved for the treatment of irritable bowel syndrome with constipation (IBS-C), and lubiprostone is approved for the treatment of IBS-C only in women as well as opioid-induced constipation in certain patients. These agents have not been studied head to head, and both drugs were compared with placebo when studied versus standard of care. In January 2017, the Food and Drug Administration approved another GC-C agonist—plecanatide (Trulance, Synergy Pharmaceuticals)—for the treatment of CIC in adults, and in January 2018, the agency approved an additional plecanatide indication for the treatment of IBS-C.7,8
Plecanatide, a GC-C agonist, is a 16-amino-acid peptide with the chemical name: L-Leucine, L-asparaginyl-L--α-aspartyl-L-α=-glutamyl-L-cysteinyl-L-α-glutamyl-L-leucyl-L-cysteinyl-Lvalyl-L-asparaginyl-L-valyl-L-alanyl-Lcysteinyl-L-threonylglycyl-Lcysteinyl-, cyclic (4→12),(7→15)-bis(disulfide). The molecular formula of plecanatide is C65H104N18O26S4, and the molecular weight is 1682 daltons. The amino acid sequence for plecanatide is shown in Figure 1. The solid lines linking cysteines illustrate disulfide bridges. Plecanatide is an amorphous white to off-white powder that is soluble in water. It is supplied as a 3-mg tablet for oral administration. The inactive ingredients consist of magnesium stearate and microcrystalline cellulose.8

Poster un Commentaire

Entry 2998 of 3943
Précédent | Suivant

Blog suivant >> Signaler un abus?Haut de page